CD274 and non-small cell lung carcinoma: Pembrolizumab + chemotherapy and nivolumab + ipilimumab are approved first-line treatment options for patients with metastatic stage IV NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%.